Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

about

A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome

P2860

Q57759536-742939E6-4A8F-49FF-B1A7-C7A72F3D4B20

P2860

Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

Item

http://www.wikidata.org/entity/Q42848307

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

@en

Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

@nl

type

Item

label

Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

@en

Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

@nl

prefLabel

Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

@en

Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

@nl

P1476

Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience

@en

P2093

European Mantle Cell Lymphoma Network

http://www.w3.org/2001/XMLSchema#string

Martin Dreyling

http://www.w3.org/2001/XMLSchema#string

P2860

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data.

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.

Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.

P304

706-708

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3324/HAEMATOL.2015.127472

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

100

http://www.w3.org/2001/XMLSchema#string

P50

Simone Ferrero

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26034112

http://www.w3.org/2001/XMLSchema#string

P932

4450615

http://www.w3.org/2001/XMLSchema#string

Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

about

P2860

P2860

Personalized medicine in lymphoma: is it worthwhile? The mantle cell lymphoma experience.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932